Search

Your search keyword '"Nos, Carlos"' showing total 267 results
Start Over Author "Nos, Carlos"
267 results on '"Nos, Carlos"'

2. Fitbeat: COVID-19 Estimation based on Wristband Heart Rate

Author

Liu, Shuo, Han, Jing, Puyal, Estela Laporta, Kontaxis, Spyridon, Sun, Shaoxiong, Locatelli, Patrick, Dineley, Judith, Pokorny, Florian B., Costa, Gloria Dalla, Leocan, Letizia, Guerrero, Ana Isabel, Nos, Carlos, Zabalza, Ana, Sørensen, Per Soelberg, Buron, Mathias, Magyari, Melinda, Ranjan, Yatharth, Rashid, Zulqarnain, Conde, Pauline, Stewart, Callum, Folarin, Amos A, Dobson, Richard JB, Bailón, Raquel, Vairavan, Srinivasan, Cummins, Nicholas, Narayan, Vaibhav A, Hotopf, Matthew, Comi, Giancarlo, and Schuller, Björn

Subjects
Electrical Engineering and Systems Science - Signal Processing, Computer Science - Human-Computer Interaction, Computer Science - Machine Learning
Abstract

This study investigates the potential of deep learning methods to identify individuals with suspected COVID-19 infection using remotely collected heart-rate data. The study utilises data from the ongoing EU IMI RADAR-CNS research project that is investigating the feasibility of wearable devices and smart phones to monitor individuals with multiple sclerosis (MS), depression or epilepsy. Aspart of the project protocol, heart-rate data was collected from participants using a Fitbit wristband. The presence of COVID-19 in the cohort in this work was either confirmed through a positive swab test, or inferred through the self-reporting of a combination of symptoms including fever, respiratory symptoms, loss of smell or taste, tiredness and gastrointestinal symptoms. Experimental results indicate that our proposed contrastive convolutional auto-encoder (contrastive CAE), i. e., a combined architecture of an auto-encoder and contrastive loss, outperforms a conventional convolutional neural network (CNN), as well as a convolutional auto-encoder (CAE) without using contrastive loss. Our final contrastive CAE achieves 95.3% unweighted average recall, 86.4% precision, anF1 measure of 88.2%, a sensitivity of 100% and a specificity of 90.6% on a testset of 19 participants with MS who reported symptoms of COVID-19. Each of these participants was paired with a participant with MS with no COVID-19 symptoms., Comment: 34pages, 4figures

Published
2021

3. Deciphering multiple sclerosis disability with deep learning attention maps on clinical MRI

Author

Coll, Llucia, Pareto, Deborah, Carbonell-Mirabent, Pere, Cobo-Calvo, Álvaro, Arrambide, Georgina, Vidal-Jordana, Ángela, Comabella, Manuel, Castilló, Joaquín, Rodríguez-Acevedo, Breogán, Zabalza, Ana, Galán, Ingrid, Midaglia, Luciana, Nos, Carlos, Salerno, Annalaura, Auger, Cristina, Alberich, Manel, Río, Jordi, Sastre-Garriga, Jaume, Oliver, Arnau, Montalban, Xavier, Rovira, Àlex, Tintoré, Mar, Lladó, Xavier, and Tur, Carmen

Published
2023
Full Text
View/download PDF

4. Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-naive Patients with High-activity, Early-stage Relapsing-remitting Multiple Sclerosis in the ENSEMBLE Study (P10-6.007)

Author

Vollmer, Timothy, primary, Bermel, Robert, additional, Brochet, Bruno, additional, Berger, Thomas, additional, Carroll, William, additional, Freedman, Mark, additional, Holmoy, Trygve, additional, Karabudak, Rana, additional, Killestein, Joep, additional, Nos, Carlos, additional, Patti, Francesco, additional, Vanopdenbosch, Ludo, additional, Kuenzel, Thomas, additional, Kadner, Karen, additional, Kulyk, Inessa, additional, and Hartung, Hans-Peter, additional

Published
2024
Full Text
View/download PDF

5. Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre

Author

Cobo-Calvo, Alvaro, Zabalza, Ana, Río, Jordi, Arrambide, Georgina, Otero-Romero, Susana, Tagliani, Paula, Cárdenas-Robledo, Simón, Castillo, Mireia, Espejo, Carmen, Rodriguez, Marta, Carbonell, Pere, Rodríguez, Breogán, Midaglia, Luciana, Vidal-Jordana, Ángela, Tur, Carmen, Galan, Ingrid, Castillo, Joaquín, Comabella, Manuel, Nos, Carlos, Auger, Cristina, Tintoré, Mar, Rovira, Àlex, Montalban, Xavier, and Sastre-Garriga, Jaume

Published
2022
Full Text
View/download PDF

6. Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing–remitting multiple sclerosis patients

Author

Río, Jordi, Rovira, Àlex, Gasperini, Claudio, Tintoré, Mar, Prosperini, Luca, Otero-Romero, Susana, Comabella, Manuel, Vidal-Jordana, Ángela, Galán, Ingrid, Midaglia, Luciana, Rodriguez-Acevedo, Breogán, Zabalza, Ana, Castilló, Joaquim, Arrambide, Georgina, Nos, Carlos, Cobo, Álvaro, Tur, Carmen, Auger, Cristina, Sastre-Garriga, Jaume, and Montalban, Xavier

Published
2022
Full Text
View/download PDF

7. Sporadic Creutzfeldt-Jakob disease VM1: phenotypic and molecular characterization of a novel subtype of human prion disease

Author

Gelpi, Ellen, Baiardi, Simone, Nos, Carlos, Dellavalle, Sofia, Aldecoa, Iban, Ruiz-Garcia, Raquel, Ispierto, Lourdes, Escudero, Domingo, Casado, Virgina, Barranco, Elena, Boltes, Anuncia, Molina-Porcel, Laura, Bargalló, Nuria, Rossi, Marcello, Mammana, Angela, Tiple, Dorina, Vaianella, Luana, Stoegmann, Elisabeth, Simonitsch-Klupp, Ingrid, Kasprian, Gregor, Klotz, Sigrid, Höftberger, Romana, Budka, Herbert, Kovacs, Gabor G., Ferrer, Isidre, Capellari, Sabina, Sanchez-Valle, Raquel, and Parchi, Piero

Published
2022
Full Text
View/download PDF

8. Fitbeat: COVID-19 estimation based on wristband heart rate using a contrastive convolutional auto-encoder

Author

Liu, Shuo, Han, Jing, Puyal, Estela Laporta, Kontaxis, Spyridon, Sun, Shaoxiong, Locatelli, Patrick, Dineley, Judith, Pokorny, Florian B., Costa, Gloria Dalla, Leocani, Letizia, Guerrero, Ana Isabel, Nos, Carlos, Zabalza, Ana, Sørensen, Per Soelberg, Buron, Mathias, Magyari, Melinda, Ranjan, Yatharth, Rashid, Zulqarnain, Conde, Pauline, Stewart, Callum, Folarin, Amos A, Dobson, Richard JB, Bailón, Raquel, Vairavan, Srinivasan, Cummins, Nicholas, Narayan, Vaibhav A, Hotopf, Matthew, Comi, Giancarlo, Schuller, Björn, and Consortium, RADAR-CNS

Published
2022
Full Text
View/download PDF

9. Global and Regional Deep Learning Models for Multiple Sclerosis Stratification From MRI.

Author

Coll, Llucia, Pareto, Deborah, Carbonell‐Mirabent, Pere, Cobo‐Calvo, Álvaro, Arrambide, Georgina, Vidal‐Jordana, Ángela, Comabella, Manuel, Castilló, Joaquín, Rodrı́guez‐Acevedo, Breogán, Zabalza, Ana, Galán, Ingrid, Midaglia, Luciana, Nos, Carlos, Auger, Cristina, Alberich, Manel, Río, Jordi, Sastre‐Garriga, Jaume, Oliver, Arnau, Montalban, Xavier, and Rovira, Àlex

Subjects
DEEP learning, MULTIPLE sclerosis, GRAY matter (Nerve tissue), CONVOLUTIONAL neural networks, RECEIVER operating characteristic curves
Abstract

Background: The combination of anatomical MRI and deep learning‐based methods such as convolutional neural networks (CNNs) is a promising strategy to build predictive models of multiple sclerosis (MS) prognosis. However, studies assessing the effect of different input strategies on model's performance are lacking. Purpose: To compare whole‐brain input sampling strategies and regional/specific‐tissue strategies, which focus on a priori known relevant areas for disability accrual, to stratify MS patients based on their disability level. Study Type: Retrospective. Subjects: Three hundred nineteen MS patients (382 brain MRI scans) with clinical assessment of disability level performed within the following 6 months (~70% training/~15% validation/~15% inference in‐house dataset) and 440 MS patients from multiple centers (independent external validation cohort). Field Strength/Sequence: Single vendor 1.5 T or 3.0 T. Magnetization‐Prepared Rapid Gradient‐Echo and Fluid‐Attenuated Inversion Recovery sequences. Assessment: A 7‐fold patient cross validation strategy was used to train a 3D‐CNN to classify patients into two groups, Expanded Disability Status Scale score (EDSS) ≥ 3.0 or EDSS < 3.0. Two strategies were investigated: 1) a global approach, taking the whole brain volume as input and 2) regional approaches using five different regions‐of‐interest: white matter, gray matter, subcortical gray matter, ventricles, and brainstem structures. The performance of the models was assessed in the in‐house and the independent external cohorts. Statistical Tests: Balanced accuracy, sensitivity, specificity, area under receiver operating characteristic (ROC) curve (AUC). Results: With the in‐house dataset, the gray matter regional model showed the highest stratification accuracy (81%), followed by the global approach (79%). In the external dataset, without any further retraining, an accuracy of 72% was achieved for the white matter model and 71% for the global approach. Data Conclusion: The global approach offered the best trade‐off between internal performance and external validation to stratify MS patients based on accumulated disability. Evidence Level: 4 Technical Efficacy: Stage 2 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Prediction of disease activity and treatment failure in relapsing–remitting MS patients initiating daily oral DMTs

Author

Pappolla, Agustin, primary, Auger, Cristina, additional, Sao-Aviles, Augusto, additional, Tur, Carmen, additional, Rodriguez-Barranco, Marta, additional, Cobo-Calvo, Álvaro, additional, Mongay-Ochoa, Neus, additional, Rodríguez-Acevedo, Breogán, additional, Zabalza, Ana, additional, Midaglia, Luciana, additional, Carbonell-Mirabent, Pere, additional, Carvajal, Rene, additional, Castilló-Justribó, Joaquín, additional, Braga, Nathane, additional, Bollo, Luca, additional, Vidal-Jordana, Angela, additional, Arrambide, Georgina, additional, Nos, Carlos, additional, Salerno, Annalaura, additional, Galán, Ingrid, additional, Comabella, Manuel, additional, Sastre-Garriga, Jaume, additional, Tintoré, Mar, additional, Rovira, Alex, additional, Montalban, Xavier, additional, and Río, Jordi, additional

Published
2024
Full Text
View/download PDF

11. A wearable device perspective on the standard definitions of disability progression in multiple sclerosis

Author

Dalla Costa, Gloria, primary, Nos, Carlos, additional, Zabalza, Ana, additional, Buron, Mathias, additional, Magyari, Melinda, additional, Sellebjerg, Finn, additional, Guerrero, Ana Isabel, additional, Roselli, Lucia, additional, La Porta, Maria Libera, additional, Martinis, Matteo, additional, Bailon, Raquel, additional, Kontaxis, Spyridon, additional, Laporta, Estela, additional, Garcia, Esther, additional, Pokorny, Florian B, additional, Schuller, Björn W, additional, Folarin, Amos, additional, Stewart, Callum, additional, Leocani, Letizia, additional, Vairavan, Srinivasan, additional, Cummins, Nicholas, additional, Dobson, Richard, additional, Hotopf, Matthew, additional, Narayan, Vaibhav, additional, Montalban, Xavier, additional, Sorensen, Per Soelberg, additional, and Comi, Giancarlo, additional

Published
2023
Full Text
View/download PDF

12. Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis

Author

Zabalza, Ana, Arrambide, Georgina, Tagliani, Paula, Cárdenas-Robledo, Simón, Otero-Romero, Susana, Esperalba, Juliana, Fernandez-Naval, Candela, Trocoli Campuzano, Jesus, Martínez Gallo, Mónica, Castillo, Mireia, Bonastre, Mercè, Resina Sallés, Mireia, Beltran, Jordina, Carbonell-Mirabent, Pere, Rodríguez-Barranco, Marta, López-Maza, Samuel, Melgarejo Otálora, Pedro José, Ruiz-Ortiz, Mariano, Pappolla, Agustin, Rodríguez Acevedo, Breogán, Midaglia, Luciana, Vidal-Jordana, Angela, Cobo-Calvo, Alvaro, Tur, Carmen, Galán, Ingrid, Castilló, Joaquín, Río, Jordi, Espejo, Carmen, Comabella, Manuel, Nos, Carlos, Sastre-Garriga, Jaume, Tintore, Mar, and Montalban, Xavier

Published
2022
Full Text
View/download PDF

13. Correction to: Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre

Author

Cobo-Calvo, Alvaro, Zabalza, Ana, Río, Jordi, Arrambide, Georgina, Otero-Romero, Susana, Tagliani, Paula, Cárdenas-Robledo, Simón, Castillo, Mireia, Espejo, Carmen, Rodriguez, Marta, Carbonell, Pere, Rodríguez, Breogán, Midaglia, Luciana, Vidal-Jordana, Ángela, Tur, Carmen, Galan, Ingrid, Castillo, Joaquín, Comabella, Manuel, Nos, Carlos, Auger, Cristina, Tintoré, Mar, Rovira, Àlex, Montalban, Xavier, and Sastre-Garriga, Jaume

Published
2022
Full Text
View/download PDF

14. A wearable device perspective on the standard definitions of disability progression in multiple sclerosis.

Author

Dalla Costa, Gloria, Nos, Carlos, Zabalza, Ana, Buron, Mathias, Magyari, Melinda, Sellebjerg, Finn, Guerrero, Ana Isabel, Roselli, Lucia, La Porta, Maria Libera, Martinis, Matteo, Bailon, Raquel, Kontaxis, Spyridon, Laporta, Estela, Garcia, Esther, Pokorny, Florian B, Schuller, Björn W, Folarin, Amos, Stewart, Callum, Leocani, Letizia, and Vairavan, Srinivasan

Subjects
*MULTIPLE sclerosis, *DISABILITIES, *CENTRAL nervous system diseases, *YOUNG adults
Abstract

Introduction: Multiple sclerosis (MS) is a leading cause of disability among young adults, but standard clinical scales may not accurately detect subtle changes in disability occurring between visits. This study aims to explore whether wearable device data provides more granular and objective measures of disability progression in MS. Methods: Remote Assessment of Disease and Relapse in Central Nervous System Disorders (RADAR-CNS) is a longitudinal multicenter observational study in which 400 MS patients have been recruited since June 2018 and prospectively followed up for 24 months. Monitoring of patients included standard clinical visits with assessment of disability through use of the Expanded Disability Status Scale (EDSS), 6-minute walking test (6MWT) and timed 25-foot walk (T25FW), as well as remote monitoring through the use of a Fitbit. Results: Among the 306 patients who completed the study (mean age, 45.6 years; females 67%), confirmed disability progression defined by the EDSS was observed in 74 patients, who had approximately 1392 fewer daily steps than patients without disability progression. However, the decrease in the number of steps experienced over time by patients with EDSS progression and stable patients was not significantly different. Similar results were obtained with disability progression defined by the 6MWT and the T25FW. Conclusion: The use of continuous activity monitoring holds great promise as a sensitive and ecologically valid measure of disability progression in MS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple Sclerosis.

Author

Villacieros‐Álvarez, Javier, Espejo, Carmen, Arrambide, Georgina, Castillo, Mireia, Carbonell‐Mirabent, Pere, Rodriguez, Marta, Bollo, Luca, Castilló, Joaquín, Comabella, Manuel, Galán, Ingrid, Midaglia, Luciana, Mongay‐Ochoa, Neus, Nos, Carlos, Rio, Jordi, Rodríguez‐Acevedo, Breogan, Sastre‐Garriga, Jaume, Tur, Carmen, Vidal‐Jordana, Angela, Vilaseca, Andreu, and Zabalza, Ana

Subjects
MYELIN oligodendrocyte glycoprotein, MULTIPLE sclerosis, OPTIC neuritis, MAGNETIC resonance imaging, ADULTS
Abstract

Objective: Myelin oligodendrocyte glycoprotein antibodies (MOG‐Ab) distinguish multiple sclerosis (MS) from MOG‐associated disease in most cases. However, studies analyzing MOG‐Ab at the time of a first demyelinating event suggestive of MS in adults are lacking. We aimed to (1) evaluate the prevalence of MOG‐Ab in a first demyelinating event suggestive of MS and (2) compare clinical and paraclinical features between seropositive (MOG‐Ab+) and seronegative (MOG‐Ab−) patients. Methods: Six hundred thirty adult patients with available serum samples obtained within 6 months from the first event were included. MOG‐Ab were analyzed using a live cell‐based assay. Statistical analyses included parametric and nonparametric tests, logistic regression, and survival models. Results: MOG‐Ab were positive in 17 of 630 (2.7%). Fourteen out of 17 (82.4%) MOG‐Ab+ patients presented with optic neuritis (ON) compared to 227of 613 (37.0%) MOG‐Ab− patients (p = 0.009). Cerebrospinal fluid‐restricted oligoclonal bands (CSF‐OBs) were found in 2 of 16 (12.5%) MOG‐Ab+ versus 371 of 601 (61.7%) MOG‐Ab− subjects (p < 0.001). Baseline brain magnetic resonance imaging (MRI) was normal in 9 of 17 (52.9%) MOG‐Ab+ versus 153 of 585 (26.2%) MOG‐Ab− patients (p = 0.029). Absence of CSF‐OBs and ON at onset were independently associated with MOG‐Ab positivity (odds ratio [OR] = 9.03, 95% confidence interval [CI] = 2.04–53.6, p = 0.009; and OR = 4.17, 95% CI = 1.15–19.8, p = 0.042, respectively). Of MOG‐Ab+ patients, 22.9% (95% CI = 0.0–42.7) compared to 67.6% (95% CI = 63.3–71.3) of MOG‐Ab− patients fulfilled McDonald 2017 criteria at 5 years (log‐rank p = 0.003). Interpretation: MOG‐Ab are infrequent in adults with a first demyelinating event suggestive of MS. However, based on our results, we suggest to determine these antibodies in those patients with ON and absence of CSF‐OBs, as long as the brain MRI is not suggestive of MS. ANN NEUROL 2024;95:116–128 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. MOG antibodies in adults with a first demyelinating event suggestive of multiple sclerosis

Author

Villacieros‐Álvarez, Javier, primary, Espejo, Carmen, additional, Arrambide, Georgina, additional, Castillo, Mireia, additional, Carbonell‐Mirabent, Pere, additional, Rodriguez, Marta, additional, Bollo, Luca, additional, Castilló, Joaquín, additional, Comabella, Manuel, additional, Galán, Ingrid, additional, Midaglia, Luciana, additional, Mongay, Neus, additional, Nos, Carlos, additional, Rio, Jordi, additional, Rodríguez‐Acevedo, Breogan, additional, Sastre‐Garriga, Jaume, additional, Tur, Carmen, additional, Vidal‐Jordana, Angela, additional, Vilaseca, Andreu, additional, Zabalza, Ana, additional, Auger, Cristina, additional, Rovira, Alex, additional, Montalban, Xavier, additional, Tintoré, Mar, additional, and Cobo‐Calvo, Álvaro, additional

Published
2023
Full Text
View/download PDF

17. Association of Very Early Treatment Initiation With the Risk of Long-Term Disability in Patients With a First Demyelinating Event

Author

Cobo-Calvo, Alvaro, primary, Tur, Carmen, additional, Otero-Romero, Susana, additional, Carbonell-Mirabent, Pere, additional, Ruiz, Mariano, additional, Pappolla, Agustin, additional, Alvarez, Javier Villacieros, additional, Vidal-Jordana, Angela, additional, Arrambide, Georgina, additional, Castilló, Joaquín, additional, Galan, Ingrid, additional, Rodríguez Barranco, Marta, additional, Midaglia, Luciana soledad, additional, Nos, Carlos, additional, Rodriguez Acevedo, Breogan, additional, Zabalza de Torres, Ana, additional, Mongay, Neus, additional, Rio, Jordi, additional, Comabella, Manuel, additional, Auger, Cristina, additional, Sastre-Garriga, Jaume, additional, Rovira, Alex, additional, Tintore, Mar, additional, and Montalban, Xavier, additional

Published
2023
Full Text
View/download PDF

18. Optic nerve region in multiple sclerosis diagnosis: the utility of visual evoked potentials

Author

Vidal-Jordana, Angela, Rovira, Alex, Arrambide, Georgina, Otero-Romero, Susana, Río, Jordi, Comabella, Manuel, Nos, Carlos, Castilló, Joaquin, Galan, Ingrid, Cabello, Sergio, Moncho, Dulce, Rahnama, Kimia, Thonon, Vanessa, Rodríguez-Acevedo, Breogan, Zabalza, Ana, Midaglia, Luciana, Auger, Cristina, Sastre-Garriga, Jaume, Montalban, Xavier, and Tintoré, Mar

Published
2020
Full Text
View/download PDF

19. Correction to: Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing–remitting multiple sclerosis patients

Author

Río, Jordi, Rovira, Àlex, Gasperini, Claudio, Tintoré, Mar, Prosperini, Luca, Otero-Romero, Susana, Comabella, Manuel, Vidal-Jordana, Ángela, Galán, Ingrid, Midaglia, Luciana, Rodriguez-Acevedo, Breogán, Zabalza, Ana, Castilló, Joaquim, Arrambide, Georgina, Nos, Carlos, Cobo-Calvo, Álvaro, Tur, Carmen, Auger, Cristina, Sastre-Garriga, Jaume, and Montalban, Xavier

Published
2022
Full Text
View/download PDF

20. Optic Nerve Topography in Multiple Sclerosis Diagnosis: The Utility of Visual Evoked Potentials

Author

Vidal-Jordana, Angela, Rovira, Alex, Arrambide, Georgina, Otero-Romero, Susana, Río, Jordi, Comabella, Manuel, Nos, Carlos, Castilló, Joaquin, Galan, Ingrid, Cabello, Sergio, Moncho, Dulce, Rahnama, Kimia, Thonon, Vanessa, Rodríguez-Acevedo, Breogan, Zabalza, Ana, Midaglia, Luciana, Auger, Cristina, Sastre-Garriga, Jaume, Montalban, Xavier, and Tintoré, Mar

Published
2021
Full Text
View/download PDF

21. Infusion-Related Reactions With Ocrelizumab: Risk Factors, Symptom Management and Patient Choices in the ENSEMBLE PLUS Study (P7-3.003)

Author

Bermel, Robert, primary, Killestein, Joep, additional, Berger, Thomas, additional, Brochet, Bruno, additional, Carroll, William, additional, Freedman, Mark, additional, Holmoy, Trygve, additional, Karabudak, Rana, additional, Nos, Carlos, additional, Patti, Francesco, additional, Ross, Amy Perrin, additional, Vanopdenbosch, Ludo, additional, Vollmer, Timothy, additional, Buffels, Regine, additional, Kadner, Karen, additional, Bortolami, Oscar, additional, and Hartung, Hans-Peter, additional

Published
2023
Full Text
View/download PDF

22. Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis; the Phase IIIb ENSEMBLE Study (S46.004)

Author

Bermel, Robert, primary, Hartung, Hans-Peter, additional, Brochet, Bruno, additional, Benedict, Ralph, additional, Berger, Thomas, additional, Carroll, William, additional, Vollmer, Timothy, additional, Holmoy, Trygve, additional, Karabudak, Rana, additional, Killestein, Joep, additional, Nos, Carlos, additional, Patti, Francesco, additional, Ross, Amy Perrin, additional, Vanopdenbosch, Ludo, additional, Wuerfel, Jens, additional, Kuenzel, Thomas, additional, Kadner, Karen, additional, Kulyk, Inessa, additional, and Freedman, Mark, additional

Published
2023
Full Text
View/download PDF

23. Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis

Author

Zuluaga, María I., Otero-Romero, Susana, Rovira, Alex, Perez-Hoyos, Santiago, Arrambide, Georgina, Negrotto, Laura, Galán, Ingrid, Río, Jordi, Comabella, Manuel, Nos, Carlos, Arévalo, María Jesús, Vidal-Jordana, Angela, Castilló, Joaquin, Rodríguez, Breogán, Midaglia, Luciana, Mulero, Patricia, Mitjana, Raquel, Auger, Cristina, Sastre-Garriga, Jaume, Montalban, Xavier, and Tintoré, Mar

Published
2019
Full Text
View/download PDF

24. Automatic Assessment of the 2-Minute Walk Distance for Remote Monitoring of People with Multiple Sclerosis.

Author

Kontaxis, Spyridon, Laporta, Estela, Garcia, Esther, Martinis, Matteo, Leocani, Letizia, Roselli, Lucia, Buron, Mathias Due, Guerrero, Ana Isabel, Zabala, Ana, Cummins, Nicholas, Vairavan, Srinivasan, Hotopf, Matthew, Dobson, Richard J. B., Narayan, Vaibhav A., La Porta, Maria Libera, Costa, Gloria Dalla, Magyari, Melinda, Sørensen, Per Soelberg, Nos, Carlos, and Bailon, Raquel

Subjects
MULTIPLE sclerosis, STATISTICAL correlation
Abstract

The aim of this study was to investigate the feasibility of automatically assessing the 2-Minute Walk Distance (2MWD) for monitoring people with multiple sclerosis (pwMS). For 154 pwMS, MS-related clinical outcomes as well as the 2MWDs as evaluated by clinicians and derived from accelerometer data were collected from a total of 323 periodic clinical visits. Accelerometer data from a wearable device during 100 home-based 2MWD assessments were also acquired. The error in estimating the 2MWD was validated for walk tests performed at hospital, and then the correlation (r) between clinical outcomes and home-based 2MWD assessments was evaluated. Robust performance in estimating the 2MWD from the wearable device was obtained, yielding an error of less than 10% in about two-thirds of clinical visits. Correlation analysis showed that there is a strong association between the actual and the estimated 2MWD obtained either at hospital (r = 0.71) or at home (r = 0.58). Furthermore, the estimated 2MWD exhibits moderate-to-strong correlation with various MS-related clinical outcomes, including disability and fatigue severity scores. Automatic assessment of the 2MWD in pwMS is feasible with the usage of a consumer-friendly wearable device in clinical and non-clinical settings. Wearable devices can also enhance the assessment of MS-related clinical outcomes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis

Author

Tur, Carmen, primary, Carbonell-Mirabent, Pere, additional, Cobo-Calvo, Álvaro, additional, Otero-Romero, Susana, additional, Arrambide, Georgina, additional, Midaglia, Luciana, additional, Castilló, Joaquín, additional, Vidal-Jordana, Ángela, additional, Rodríguez-Acevedo, Breogán, additional, Zabalza, Ana, additional, Galán, Ingrid, additional, Nos, Carlos, additional, Salerno, Annalaura, additional, Auger, Cristina, additional, Pareto, Deborah, additional, Comabella, Manuel, additional, Río, Jordi, additional, Sastre-Garriga, Jaume, additional, Rovira, Àlex, additional, Tintoré, Mar, additional, and Montalban, Xavier, additional

Published
2022
Full Text
View/download PDF

26. Lesion topographies in multiple sclerosis diagnosis: A reappraisal

Author

Arrambide, Georgina, Tintore, Mar, Auger, Cristina, Río, Jordi, Castilló, Joaquín, Vidal-Jordana, Angela, Galán, Ingrid, Nos, Carlos, Comabella, Manuel, Mitjana, Raquel, Mulero, Patricia, de Barros, Andrea, Rodríguez-Acevedo, Breogán, Midaglia, Luciana, Sastre-Garriga, Jaume, Rovira, Alex, and Montalban, Xavier

Published
2017
Full Text
View/download PDF

27. The kappa free light chain index and oligoclonal bands have a similar role in the McDonald criteria

Author

Arrambide, Georgina, primary, Espejo, Carmen, additional, Carbonell-Mirabent, Pere, additional, Dieli-Crimi, Romina, additional, Rodríguez-Barranco, Marta, additional, Castillo, Mireia, additional, Auger, Cristina, additional, Cárdenas-Robledo, Simón, additional, Castilló, Joaquín, additional, Cobo-Calvo, Álvaro, additional, Galán, Ingrid, additional, Midaglia, Luciana, additional, Nos, Carlos, additional, Otero-Romero, Susana, additional, Río, Jordi, additional, Rodríguez-Acevedo, Breogán, additional, Ruiz-Ortiz, Mariano, additional, Salerno, Annalaura, additional, Tagliani, Paula, additional, Tur, Carmen, additional, Vidal-Jordana, Angela, additional, Zabalza, Ana, additional, Sastre-Garriga, Jaume, additional, Rovira, Alex, additional, Comabella, Manuel, additional, Hernández-González, Manuel, additional, Montalban, Xavier, additional, and Tintore, Mar, additional

Published
2022
Full Text
View/download PDF

29. Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?

Author

Zabalza, Ana, primary, Arrambide, Georgina, additional, Otero-Romero, Susana, additional, Pappolla, Agustín, additional, Tagliani, Paula, additional, López-Maza, Samuel, additional, Cárdenas-Robledo, Simón, additional, Esperalba, Juliana, additional, Fernández-Naval, Candela, additional, Martínez-Gallo, Monica, additional, Castillo, Mireia, additional, Bonastre, Mercè, additional, Resina-Salles, Mireia, additional, Bertran, Jordina, additional, Rodriguez-Barranco, Marta, additional, Carbonell-Mirabent, Pere, additional, Gonzalez, Marina, additional, Merchan, Miguel, additional, Quiroga-Varela, Ana, additional, Miguela, Albert, additional, Gómez, Imma, additional, Álvarez, Gary, additional, Robles, René, additional, Perez del Campo, Dúnia, additional, Queralt, Xavier, additional, Soler, Maria José, additional, Agraz, Irene, additional, Martinez-Valle, Fernando, additional, Rodríguez-Acevedo, Breogán, additional, Midaglia, Luciana, additional, Vidal-Jordana, Ángela, additional, Cobo-Calvo, Álvaro, additional, Tur, Carmen, additional, Galan, Ingrid, additional, Castillo, Joaquín, additional, Río, Jordi, additional, Espejo, Carmen, additional, Comabella, Manuel, additional, Nos, Carlos, additional, Sastre-Garriga, Jaume, additional, Ramió-Torrentà, Lluís, additional, Tintoré, Mar, additional, and Montalban, Xavier, additional

Published
2022
Full Text
View/download PDF

30. Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis

Author

Tur, Carmen, Carbonell-Mirabent, Pere, Cobo-Calvo, Álvaro, Otero-Romero, Susana, Arrambide, Georgina, Midaglia, Luciana, Castilló, Joaquín, Vidal-Jordana, Angela, Rodríguez Acevedo, Breogán, Zabalza, Ana, Galan, Ingrid, Nos, Carlos, Salerno, Annalaura, Auger, Cristina, Pareto, Deborah, Comabella, Manuel, Río, Jordi, Sastre-Garriga, Jaume, Rovira, Alex, Tintoré, Mar, Montalban, Xavier, and Universitat Autònoma de Barcelona

Subjects
Neurology (clinical)
Abstract

This cohort study investigates the long-term outcomes of patients who develop progression independent of relapse activity after a first demyelinating event in multiple sclerosis. What are the long-term outcomes of patients developing progression independent of relapse activity (PIRA) after a first demyelinating event in multiple sclerosis? In this longitudinal cohort study including 1128 patients with a first demyelinating event in multiple sclerosis, presenting with PIRA was associated with significantly shorter times to developing severe disability compared with not presenting with PIRA. Patients presenting with PIRA within the first 5 years of multiple sclerosis had a significantly 26-fold greater risk of developing severe disability than patients whose first PIRA appeared late in the disease. Results suggest that presenting with PIRA after a first demyelinating event in multiple sclerosis is an ominous prognosis, especially if it occurs early in the disease course. Progression independent of relapse activity (PIRA) is the main event responsible for irreversible disability accumulation in relapsing multiple sclerosis (MS). To investigate clinical and neuroimaging predictors of PIRA at the time of the first demyelinating attack and factors associated with long-term clinical outcomes of people who present with PIRA. This cohort study, conducted from January 1, 1994, to July 31, 2021, included patients with a first demyelinating attack from multiple sclerosis; patients were recruited from 1 study center in Spain. Patients were excluded if they refused to participate, had alternative diagnoses, did not meet protocol requirements, had inconsistent demographic information, or had less than 3 clinical assessments. Exposures included (1) clinical and neuroimaging features at the first demyelinating attack and (2) presenting PIRA, ie, confirmed disability accumulation (CDA) in a free-relapse period at any time after symptom onset, within (vs after) the first 5 years of the disease (ie, early/late PIRA), and in the presence (vs absence) of new T2 lesions in the previous 2 years (ie, active/nonactive PIRA). Expanded Disability Status Scale (EDSS) yearly increase rates since the first attack and adjusted hazard ratios (HRs) for predictors of time to PIRA and time to EDSS 6.0. Of the 1128 patients (mean [SD] age, 32.1 [8.3] years; 781 female individuals [69.2%]) included in the study, 277 (25%) developed 1 or more PIRA events at a median (IQR) follow-up time of 7.2 (4.6-12.4) years (for first PIRA). Of all patients with PIRA, 86 of 277 (31%) developed early PIRA, and 73 of 144 (51%) developed active PIRA. Patients with PIRA were slightly older, had more brain lesions, and were more likely to have oligoclonal bands than those without PIRA. Older age at the first attack was the only predictor of PIRA (HR, 1.43; 95% CI, 1.23-1.65; P

Published
2023

31. The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS

Author

Tintoré, Mar, Arrambide, Georgina, Otero-Romero, Susana, Carbonell-Mirabent, Pere, Río, Jordi, Tur, Carmen, Comabella, Manuel, Nos, Carlos, Arévalo, María Jesús, Anglada, Elisenda, Menendez, Rebeca, Midaglia, Luciana, Galán, Ingrid, Vidal-Jordana, Angela, Castilló, Joaquin, Mulero, P, Zabalza, Ana, Rodríguez-Acevedo, Breogan, Rodriguez, Marta, Espejo, Carmen, Sequeira, Joao, Mitjana, Raquel, de Barros, Andrea, Pareto, Deborah, Auger, Cristina, Pérez-Hoyos, Santiago, Sastre-Garriga, Jaume, Rovira, Alex, Montalban, Xavier, and Universitat Autònoma de Barcelona

Subjects
Pediatrics, medicine.medical_specialty, Multiple Sclerosis, 030218 nuclear medicine & medical imaging, Multiple sclerosis, Cohort Studies, 03 medical and health sciences, Disability Evaluation, 0302 clinical medicine, medicine, Long term outcomes, Humans, Disease-modifying treatment, business.industry, disease-modifying treatment, Brain, prediction, medicine.disease, Prognosis, INCEPTION COHORT, Clinically isolated syndromes, Magnetic Resonance Imaging, Neurology, Disease Progression, Neurology (clinical), prognosis, business, Prediction, Original Research Papers, 030217 neurology & neurosurgery, MRI, Demyelinating Diseases
Abstract

Altres ajuts: This study has been funded by European Regional Development Fund and co-funded by Instituto Carlos III. It has also received support by a grant from Genzyme foundation (GENZYME-2015-01) granted to M.T. and from the 'Red Española de Esclerosis Múltiple (REEM)', which is sponsored by FIS, the Instituto de Salud Carlos III, the Ministry of Economy and Competitiveness in Spain, and the 'Ajuts per donar Suport als Grups de Recerca de Catalunya', which is sponsored by the 'Agència de Gestió d'Ajuts Universitaris i de Recerca' (AGAUR) of the Generalitat de Catalunya in Spain. To explore the long-term outcomes of patients with clinically isolated syndromes from the Barcelona cohort. We selected patients with a follow-up longer than 10 years to (1) estimate the risks of multiple sclerosis (MS) and disability accumulation according to the baseline number of T2 lesions and to compare treated versus untreated patients and early versus delayed treatment, and (2) to study baseline features of patients with aggressive MS (Expanded Disability Status Scale (EDSS) ⩾6.0 at 10 years). In all, 401 patients were included (mean follow-up of 14.4 (standard deviation of 2.9) years). A higher number of T2 lesions was associated with an earlier MS diagnosis and an earlier risk of irreversible disability. Early treatment was associated with a decreased risk of EDSS of 3.0: adjusted hazard ratio = 0.4, 95% confidence interval = (0.2, 0.7). Patients with aggressive MS differed in their baseline brain magnetic resonance images: The median (interquartile range) number of T2 lesions and contrast-enhancing lesions (CEL) was 71 (28-95) versus 7 (1-19) and 3 (1-24) versus 0 (0-1), respectively. The cut-offs that better classified patients with aggressive MS were 20 for T2 lesions and 2 for CEL. Although MS natural history is changing, a high lesion load at onset is helpful to identify patients at risk of presenting an aggressive MS.

Published
2019

32. Correction to: Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing–remitting multiple sclerosis patients

Author

Río, Jordi, primary, Rovira, Àlex, additional, Gasperini, Claudio, additional, Tintoré, Mar, additional, Prosperini, Luca, additional, Otero-Romero, Susana, additional, Comabella, Manuel, additional, Vidal-Jordana, Ángela, additional, Galán, Ingrid, additional, Midaglia, Luciana, additional, Rodriguez-Acevedo, Breogán, additional, Zabalza, Ana, additional, Castilló, Joaquim, additional, Arrambide, Georgina, additional, Nos, Carlos, additional, Cobo-Calvo, Álvaro, additional, Tur, Carmen, additional, Auger, Cristina, additional, Sastre-Garriga, Jaume, additional, and Montalban, Xavier, additional

Published
2021
Full Text
View/download PDF

33. Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome

Author

Tintore, Mar, primary, Cobo-Calvo, Alvaro, additional, Carbonell, Pere, additional, Arrambide, Georgina, additional, Otero-Romero, Susana, additional, Río, Jordi, additional, Tur, Carmen, additional, Comabella, Manuel, additional, Nos, Carlos, additional, Arévalo, María Jesús, additional, Midaglia, Luciana, additional, Galán, Ingrid, additional, Vidal-Jordana, Angela, additional, Castilló, Joaquin, additional, Rodríguez-Acevedo, Breogán, additional, Zabalza de Torres, Ana, additional, Salerno, Annalaura, additional, Auger, Cristina, additional, Sastre-Garriga, Jaume, additional, Rovira, Àlex, additional, and Montalban, Xavier, additional

Published
2021
Full Text
View/download PDF

34. Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing–remitting multiple sclerosis patients

Author

Río, Jordi, primary, Rovira, Àlex, additional, Gasperini, Claudio, additional, Tintoré, Mar, additional, Prosperini, Luca, additional, Otero-Romero, Susana, additional, Comabella, Manuel, additional, Vidal-Jordana, Ángela, additional, Galán, Ingrid, additional, Midaglia, Luciana, additional, Rodriguez-Acevedo, Breogán, additional, Zabalza, Ana, additional, Castilló, Joaquim, additional, Arrambide, Georgina, additional, Nos, Carlos, additional, Cobo, Álvaro, additional, Tur, Carmen, additional, Auger, Cristina, additional, Sastre-Garriga, Jaume, additional, and Montalban, Xavier, additional

Published
2021
Full Text
View/download PDF

38. Optic Nerve Topography in Multiple Sclerosis Diagnosis

Author

Vidal-Jordana, Angela, Rovira, Alex, Arrambide, Georgina, Otero-Romero, Susana, Río, Jordi, Comabella, Manuel, Nos, Carlos, Castilló, Joaquín, Galan, Ingrid, Cabello, Sergio, Moncho, Dulce, Rahnama, Kimia, Thonon, Vanessa, Rodríguez-Acevedo, Breogán, Zabalza, Ana, Midaglia, Luciana, Auger, Cristina, Sastre-Garriga, Jaume, Montalban, Xavier, Tintoré, Mar, and Universitat Autònoma de Barcelona

Subjects
CIS, genetic structures, Optic nerve, Visual evoked potentials, MS diagnosis
Abstract

To assess the added value of the optic nerve region (by using visual evoked potentials [VEPs]) to the current diagnostic criteria. From the Barcelona clinically isolated syndrome (CIS) cohort, patients with complete information to assess dissemination in space (DIS), the optic nerve region, and dissemination in time at baseline (n = 388) were selected. Modified DIS (modDIS) criteria were constructed by adding the optic nerve to the current DIS regions. The DIS and modDIS criteria were evaluated with univariable Cox proportional hazard regression analyses with the time to the second attack as the outcome. A subset of these patients who had at least 10 years of follow-up or a second attack occurring within 10 years (n = 151) were selected to assess the diagnostic performance. The analyses were also performed according to CIS topography (optic neuritis vs non-optic neuritis). The addition of the optic nerve as a fifth region improved the diagnostic performance by slightly increasing the accuracy (2017 DIS 75.5%, modDIS 78.1%) and the sensitivity (2017 DIS 79.2%, modDIS 82.3%) without lowering the specificity (2017 DIS 52.4%, modDIS 52.4%). When the analysis was conducted according to CIS topography, the modDIS criteria performed similarly in both optic neuritis and non-optic neuritis CIS. The addition of the optic nerve, assessed by VEP, as a fifth region in the current DIS criteria slightly improves the diagnostic performance because it increases sensitivity without losing specificity.

Published
2021

39. Recently Diagnosed Early-Stage RRMS: NEDA, ARR, Disability Progression, Serum Neurofilament and Safety: 1-Year Interim Data From the Ocrelizumab Phase IIIb ENSEMBLE Study (2261)

Author

Vollmer, Timothy, primary, Freedman, Mark S., additional, Killestein, Joep, additional, Nos, Carlos, additional, Vanopdenbosch, Ludo, additional, Buffels, Regine, additional, Kadner, Karen, additional, Kuenzel, Thomas, additional, Kulyk, Inessa, additional, and Hartung, Hans-Peter, additional

Published
2021
Full Text
View/download PDF

40. Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset.

Author

Otero‐Romero, Susana, Midaglia, Luciana, Carbonell‐Mirabent, Pere, Zuluaga, María, Galán, Ingrid, Río, Jordi, Arrambide, Georgina, Rodríguez‐Barranco, Marta, Vidal‐Jordana, Angela, Castillo, Joaquin, Rodríguez‐Acevedo, Breogán, Zabalza, Ana, Nos, Carlos, Comabella‐Lopez, Manuel, Mulero, Patricia, Auger, Cristina, Sastre‐Garriga, Jaume, Pérez‐Hoyos, Santiago, Rovira, Alex, and Montalban, Xavier

Subjects
MULTIPLE sclerosis, HOT flashes, MENOPAUSE, GENITOURINARY diseases, AGE factors in disease, DISEASE duration, DISABILITIES
Abstract

Background and purpose: To evaluate the effect of menopause on disability accumulation in women followed from their clinically isolated syndrome (CIS). Methods: We examined the longitudinal changes in Expanded Disability Status Scale (EDSS) scores from CIS until the last follow‐up in women belonging to the Barcelona CIS prospective cohort, followed through their menopausal transition. The analysis is based on 13,718 EDSS measurements, with an average of 28 EDSS measurements per patient. Differences in EDSS trajectories between menopausal and nonmenopausal women, controlling for age and disease duration, were evaluated. We performed two sensitivity analyses in women with confirmed MS and in those experiencing early menopause. Results: From 764 eligible women, 496 (65%) responded to the questionnaire, and 74 (14.9%) reached menopause over the follow‐up. We did not find a significant inflection point in EDSS trajectories around menopause (slope change −0.009; 95% CI −0.066; 0.046). The annual increase in EDSS over the complete course of the disease was significantly higher in menopausal women (0.049; 95% CI, 0.026–0.074) versus nonmenopausal (0.019; 95% CI, 0.008–0.031; interaction p value 0.025). This difference was lost when controlling for age and disease duration (EDSS annual increase of 0.059; 95% CI, 0.025–0.094 vs. 0.038; 95% CI, 0.021–0.057, respectively; interaction p value 0.321). No inflection point was detected when the analysis was restricted to women with confirmed MS or with earlier menopause. Conclusions: Menopause is not associated with an increased risk of disability in a CIS population, considering EDSS trajectories throughout the course of the disease together with age and disease duration. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset

Author

Otero‐Romero, Susana, primary, Midaglia, Luciana, additional, Carbonell‐Mirabent, Pere, additional, Zuluaga, María, additional, Galán, Ingrid, additional, Río, Jordi, additional, Arrambide, Georgina, additional, Rodríguez‐Barranco, Marta, additional, Vidal‐Jordana, Angela, additional, Castillo, Joaquin, additional, Rodríguez‐Acevedo, Breogán, additional, Zabalza, Ana, additional, Nos, Carlos, additional, Comabella‐Lopez, Manuel, additional, Mulero, Patricia, additional, Auger, Cristina, additional, Sastre‐Garriga, Jaume, additional, Pérez‐Hoyos, Santiago, additional, Rovira, Alex, additional, Montalban, Xavier, additional, and Tintoré, Mar, additional

Published
2021
Full Text
View/download PDF

42. The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia

Author

Midaglia, Luciana, primary, Sastre-Garriga, Jaume, additional, Pappolla, Agustín, additional, Quibus, Laura, additional, Carvajal, René, additional, Vidal-Jordana, Angela, additional, Arrambide, Georgina, additional, Río, Jordi, additional, Comabella, Manuel, additional, Nos, Carlos, additional, Castilló, Joaquin, additional, Galan, Ingrid, additional, Rodríguez-Acevedo, Breogan, additional, Auger, Cristina, additional, Tintoré, Mar, additional, Montalban, Xavier, additional, and Rovira, Àlex, additional

Published
2021
Full Text
View/download PDF

43. COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response

Author

Zabalza, Ana, primary, Cárdenas‐Robledo, Simón, additional, Tagliani, Paula, additional, Arrambide, Georgina, additional, Otero‐Romero, Susana, additional, Carbonell‐Mirabent, Pere, additional, Rodriguez‐Barranco, Marta, additional, Rodríguez‐Acevedo, Breogán, additional, Restrepo Vera, Juan Luis, additional, Resina‐Salles, Mireia, additional, Midaglia, Luciana, additional, Vidal‐Jordana, Angela, additional, Río, Jordi, additional, Galan, Ingrid, additional, Castillo, Joaquin, additional, Cobo‐Calvo, Álvaro, additional, Comabella, Manuel, additional, Nos, Carlos, additional, Sastre‐Garriga, Jaume, additional, Tintore, Mar, additional, and Montalban, Xavier, additional

Published
2021
Full Text
View/download PDF

44. Optic Nerve Topography in Multiple Sclerosis Diagnosis

Author

Vidal-Jordana, Angela, primary, Rovira, Alex, additional, Arrambide, Georgina, additional, Otero-Romero, Susana, additional, Río, Jordi, additional, Comabella, Manuel, additional, Nos, Carlos, additional, Castilló, Joaquin, additional, Galan, Ingrid, additional, Cabello, Sergio, additional, Moncho, Dulce, additional, Rahnama, Kimia, additional, Thonon, Vanessa, additional, Rodríguez-Acevedo, Breogan, additional, Zabalza, Ana, additional, Midaglia, Luciana, additional, Auger, Cristina, additional, Sastre-Garriga, Jaume, additional, Montalban, Xavier, additional, and Tintoré, Mar, additional

Published
2020
Full Text
View/download PDF

49. Cognitive Impairment and MRI-based Disease Progression in MS PATHS: Variable Susceptibility Across the Lifespan (1334)

Author

Charvet, Leigh, primary, de Moor, Carl, additional, Fitzgerald, Kathryn, additional, Galioto, Rachel, additional, Hersh, Carrie M., additional, Hua, Le, additional, Hyland, Megan H., additional, Krupp, Lauren, additional, Liao, Shirley, additional, Montelban, Xavier, additional, Mowry, Ellen M., additional, Nicholas, Jacqueline A., additional, Nos, Carlos, additional, Rensel, Mary, additional, Rao, Stephen, additional, Rudick, Richard A., additional, Ryerson, Lana Zhovtis, additional, Tinoré, Mar, additional, Ziemssen, Tjalf, additional, Fisher, Elizabeth, additional, and Williams, James, additional

Published
2020
Full Text
View/download PDF

50. Patterns of Cognitive and Physical Impairment In A Large, Heterogeneous MS Population: Results From MS PATHS (1333)

Author

Ziemssen, Tjalf, primary, Tintoré, Mar, additional, de Moor, Carl, additional, Edwards, Michael R., additional, Fisher, Elizabeth, additional, Galioto, Rachel, additional, Hersh, Carrie M., additional, Hyland, Megan H., additional, Koulinska, Irene, additional, McGinley, Marisa, additional, Montalban, Xavier, additional, Mowry, Ellen M., additional, Nos, Carlos, additional, Ontaneda, Dan, additional, Rao, Stephen, additional, Rensel, Mary, additional, Ryerson, Lana Zhovtis, additional, Wang, Yujie, additional, Williams, James R., additional, Xiong, Kuangnan, additional, and Rudick, Richard A., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results